Ovarian tumor: a review


  • Poonam Kashyap Department of Obstetrics and Gynaecology, Maualana Azad Medical College, New Delhi, India




Ovarian cancers, Neoplasia, PARP


Ovarian cancers are the 7th most common cancers in women. It is found more commonly in elderly age group. The survival depends on the stage of diagnosis and many of the patients present in advanced disease when the prognosis becomes dismal. The dilemma is to differentiate them from benign disease so that the unwanted laparotomies could be saved. Biomarkers and radiological classification may play a role in differentiating benign from malignant and deciding on the management. There is no screening method to diagnose ovarian cancers and the patient presents with nonspecific complaints missing them in early stages. Optimal cytoreduction is required for better overall survival, progression free survival and response to adjuvant chemotherapy. Those women having history of breast, ovary, endometrial, colorectal cancers should be screened for malignancies and genetic testing is advised. Surgery is the mainstay of treatment followed by chemotherapy. Risk reducing salpingoophorectomy can be offered to women having BRCA1 and BRCA2 mutation carriers after they complete their family. The area of target therapies is the most recent and promising in treatment of ovarian cancer. They are coming in forefront when chemotherapy toxicity, drug resistance are big hurdles in treatment of ovarian cancer. With recent advances and understanding of the biology of ovarian cancer have led to clinical trials of targeted agents. The  angiogenesis inhibitors and polyadenosine diphosphate-ribose polymerase (PARP) inhibitors are the most developed.

Author Biography

Poonam Kashyap, Department of Obstetrics and Gynaecology, Maualana Azad Medical College, New Delhi, India

consultant in obstetrics and gynae


Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Momenimovahed. Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health. 2019:11.

Ehdaivand S. WHO classification. Pathology Outlines. SB Coburn, F Bray, ME Sherman, B Trabert. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J can 2017;140(11):2451-60.

DiSaia PJ, Creasman WT, Mannel RS, McMeekin DS. Clinical gynecologic oncology e-book. Elsevier Health Sci. 2017;4.

Ovarian cancer: recognition and initial management. Clin guideline. NICE. 2020;2011.

Valentini AL, Gui B, Miccò M. Benign and Suspicious Ovarian Masses-MR Imaging Criteria for Characterization: Pictorial Review. J Oncol. 2012;2012:481-806.

Imaoka I, Wada A, Kaji Y. Developing an MR imaging strategy for diagnosis of ovarian masses. Radiographics. 2006;26(5):1431-48.

Heilbrun ME, Olpin J, Shaaban A. Imaging of benign adnexal masses: characteristic presentations on ultrasound, computed tomography, and magnetic resonance imaging. Clin Obstetr Gynecol. 2009;52(1):21-39.

Shaaban AM, Rezvani M, Elsayes KM, Baskin H. Ovarian Malignant Germ Cell Tumors: Cellular Classification and Clinical and Imaging Features. Radio Graphics. 2014;34:777-801.

Smith HO, Berwick M, Verschraegen CF. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075-85.

Smith HO, Berwick M, Verschraegen CF. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075-85.

Norris HJ, Jensen RD. Relative frequency of ovarian neoplasms in children and adolescents. Cancer. 1972;30(3):713-9.

Heifetz SA, Cushing B, Giller R. Immature teratomas in children: pathologic considerations-a report from the combined Pediatric Oncology Group/Children’s Cancer Group. Am J Surg Pathol. 1998;22(9):1115-24.

Kawai M, Kano T, Kikkawa F. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol. 1992;45(3):248-53.

Mitchell DG, Javitt MC, Glanc P, Bennett GL. American College of Radiology. ACR appropriateness criteria staging and follow-up of ovarian cancer. J Am Coll Radiol. 2013;10(11):822-7.

NCCN guideline. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version. 2021;2021:6.

Royal College of Obstetrics and Gynaecologists. Management of Suspected Ovarian Masses in Premenopausal Women. Green-top Guideline. London: RCOG. 2011;62.

Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound. 1997;25:217-25.

Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni AA. Transvaginal ultrasonographic Characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound Obstet Gynecol. 1997;10:192-7.

Xu Y, Zhong R, He J. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: Results from 1021 cases in South China. Clin Biochem. 2016;49(1-2):32-40.

Timmerman D, Van Calster B, Testa AC. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol. 2016;214(4):424-37.

Van Calster B, Van Hoorde K, Valentin L. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ. 2014;349:g5920.

Timmerman D, Van Calster B, Testa AC. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound Obstet Gynecol. 2010;36(2):226-34.

Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med. 1992;11:631-8.

Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016;5(1):41-4.

Dunton CJ, Eskander RN, Bullock RG, Pappas T. Low-risk multivariate index assay scores, physician referral and surgical choices in women with adnexal masses. Curr Med Res Opin. 2020;36(12):2079-83.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version I. Fort Washington, PA: NCCN;2017.

Van Leeuwen FE, Klip H, Mooij TM et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456-65.

Kurman RJ, Visvanathan K, Roden R. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2018;198:351-6.

Antoniou AC, Pharoah PD, Easton DF, Evans DG. BRCA1 and BRCA2 cancer risks. J Clin Oncol. 2006;24(20):3312-14.

Struewing JP, Hartge P, Wacholder S. The risk of cancer associated with specifi c mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336(20):1401-8.

Kauff N, Domchek S, Friebel T. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1 and BRCA2 associated breast and gynecologic cancer: a multi-center, prospective study. J Clin Oncol. 2008;26(8):1331-7.

Van Leeuwen FE, Klip H, Mooij TM. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456-65.

Colombo N, Sessa C, du Bois A. Int J Gynecol Cancer2019;0:1-33.

Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-44.

Hubner M. Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPeritoneal Chemotherapy (HIPEC): Enhanced recovery after surfery (ERAS) Society Recommendations-Part II: Postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311-23.

Serov SF, Scully RE, Sobin LH. International Histological Classification of Tumors. No. 9. Histological Typing of Ovarian Tumours. WHO, Geneva. 1973;1-56.

NCCN guideline. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 2. 2021;2020.

Ray-Coquard I. Olaparib plus Bevacizumab as First- Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381:2416-28.

American Joint Committee on Cancer. Ovary, Fallopian Tube, and Primary Peritoneal carcinoma. In: AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer. 2017;681-90.






Review Articles